Biomarkers in the "Omics" Era

A special issue of BioTech (ISSN 2673-6284).

Deadline for manuscript submissions: closed (31 July 2022) | Viewed by 16969

Special Issue Editors


E-Mail Website
Guest Editor
Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway
Interests: precision medicine; patients stratification; prostate cancer; molecular signatures; androgen receptor; MYC; bromodomain; chromatin; transcriptomics; single cell; gene regulation; radiobiology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Division of Medical Oncology, S. Orsola-Malpighi University Hospital, Bologna, Italy
Interests: hepato-biliary-pancreatic cancers; translational medicine; cancer risk factors; cancer biomarkers; cancer genetic; cancer biology; drug discovery; cancer treatment

Special Issue Information

The rapid development of high-throughput technologies has opened up a new “omics” era providing an unprecedented opportunity for scientists and clinicians to gain deeper insights into molecular mechanisms, even at single cell resolution. The analysis and integration of the data arising from these methodological approaches is revolutionizing daily clinical practice, moving the precision medicine paradigm forward. In this scenario, the identification of tissue and circulating molecular biomarkers with high sensitivity and specificity to be employed for diagnosis, prognosis, and treatment prediction will undoubtedly benefit patients, but only few have been successfully implemented into the clinic.

This Special Issue of BioTech includes research articles, short reports, and reviews focused on the employment of “omics” (e.g., genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics, microbiomics) technologies for biomarker development both at translational and clinical level.

Dr. Alfonso Urbanucci
Dr. Simona Tavolari
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. BioTech is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords


  • gene signatures
  • oncology
  • free circulating DNA
  • next-generation sequencing
  • molecular biomarkers

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

17 pages, 3071 KiB  
Review
Applications of CRISPR-Cas9 as an Advanced Genome Editing System in Life Sciences
by Kamand Tavakoli, Alireza Pour-Aboughadareh, Farzad Kianersi, Peter Poczai, Alireza Etminan and Lia Shooshtari
BioTech 2021, 10(3), 14; https://0-doi-org.brum.beds.ac.uk/10.3390/biotech10030014 - 06 Jul 2021
Cited by 22 | Viewed by 16056
Abstract
Targeted nucleases are powerful genomic tools to precisely change the target genome of living cells, controlling functional genes with high exactness. The clustered regularly interspaced short palindromic repeats associated protein 9 (CRISPR-Cas9) genome editing system has been identified as one of the most [...] Read more.
Targeted nucleases are powerful genomic tools to precisely change the target genome of living cells, controlling functional genes with high exactness. The clustered regularly interspaced short palindromic repeats associated protein 9 (CRISPR-Cas9) genome editing system has been identified as one of the most useful biological tools in genetic engineering that is taken from adaptive immune strategies for bacteria. In recent years, this system has made significant progress and it has been widely used in genome editing to create gene knock-ins, knock-outs, and point mutations. This paper summarizes the application of this system in various biological sciences, including medicine, plant science, and animal breeding. Full article
(This article belongs to the Special Issue Biomarkers in the "Omics" Era)
Show Figures

Figure 1

Back to TopTop